Skip to main content
Clinical Trials/EUCTR2011-000430-11-ES
EUCTR2011-000430-11-ES
Active, not recruiting
Phase 1

Transradial access versus Femoral and Bivalirudin versus unfractionated heparin with or without glycoprotein IIb/IIIa inhibitors as a global strategy to minimize bleeding complications in patients with acute coronary syndrome subjected to invasive treatment (MATRIX). - Matrix

Società Italian di Cardiologia Invasiva GISE0 sites6,800 target enrollmentJune 4, 2014

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Patients with acute coronary syndrome (ACS) with or without ST-segment elevation who undergo CATH ± PCI
Sponsor
Società Italian di Cardiologia Invasiva GISE
Enrollment
6800
Status
Active, not recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 4, 2014
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional clinical trial of medicinal product

Investigators

Sponsor
Società Italian di Cardiologia Invasiva GISE

Eligibility Criteria

Inclusion Criteria

  • All patients with acute coronary syndrome (ACS) with or without ST\-segment elevation who undergo angiography coronary ± angioplasty (PCI) and that eligible for treatment with both access sites trans\-radial and trans\-femoral will be enrolled on consecutive basic.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 6800
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 6800

Exclusion Criteria

  • 1\.Patients who can not give informed consent or have a life expectancy of \<30 days.
  • 2\.Allergy/intolerance to bivalirudin or unfractionated heparin.
  • 3\.Stable or silent CAD as indication to coronary angiography.
  • 4\.Treatment with LWMH within the past 6 hours.
  • 5\.Treatment with any GPI in the previous 3 days.
  • 6\.Absolute contraindications or allergy that cannot be pre\-medicated to iodinated contrast or to any of the study medications including both aspirin and clopidogrel.
  • 7\.Contraindications to angiography, including but not limited to severe peripheral vascular disease.
  • 8\.If it is known, pregnant or nursing mothers. Women of child\-bearing age will be asked if they are pregnant or think that they may be pregnant.
  • 9\.If it is known, a creatinine clearance \<30 mL/min or dialysis dependent.
  • 10\.Previous enrolment in this study.

Outcomes

Primary Outcomes

Not specified

Similar Trials